간 전이를 동반한 대장암 치료의 최신지견 = Recent advances in the treatment of patients with colorectal Liver metastases

다국어 초록 (Multilingual Abstract)

Colorectal cancer (CRC) is 2nd to 3rd common cancer and the annual incidence of CRC is increasing in Korea. The liver is the most frequent metastatic site of colorectal cancer and approximately one forth of patients presents with liver metastasis at initial diagnosis. Without treatment, patients with colorectal liver metastasis (CRLM) have a poor prognosis; however, long-term survival benefits and even cure have been reported in a portion of patients undergoing surgical resection of liver metastasis. In addition, advances in chemotherapeutic agents, imaging, and surgical techniques can increase the number of patients who are eligible for curative resection. In the past 10 years, combination chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin or irinotecan was becoming the standard chemotherapy of treatment for metastatic CRC including CRLM. Furthermore, the combined use of targeted agents, such as cetuximab and bevacizumab, plus standard chemotherapeutics revealed more improvements in response rates and survival. Even in patients with resectable CRLM, perioperative chemotherapy with surgical resection could improve in progression free survival. However, the curable portion of patients with CRLM was still less than 20~30%, more detail management based on multidisciplinary team approaches should be needed. (Korean J Med 79:125-132, 2010)

참고문헌 (Reference)

1 Van Cutsem E, "Towards a pan-European consensus on the treatment of patients with colorectal liver metastases" 42 : 2212-2221, 2006

2 Figueras J, "Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients" 50 : 478-488, 2007

3 Nordlinger B, "Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients" Association Francaise de Chirurgie. 77 : 1254-1262, 1996

4 Cassidy J, "Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT)+bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966" 26 (26): 2008

5 Bismuth H, "Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy" 224 : 509-520, 1996

6 Adam R, "Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival" 240 : 644-657, 2004

7 Folprecht G, "Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CLM)" 19 (19): viii168-, 2008

8 Kopetz S, "Preliminary results from a phase II study of infusional 5-FU, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC)" 24 (24): 2006

9 Falcone A, "Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest" 25 : 1670-1676, 2007

10 Nordlinger B, "Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial" 371 : 1007-1016, 2008

11 Simmonds PC, "Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis" 321 : 531-535, 2000

12 Alberts SR, "Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study" 23 : 9243-9249, 2005

13 Kornprat P, "Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy" 14 : 1151-1160, 2007

14 Pozzo C, "Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients" 15 : 933-939, 2004

15 Folprecht G, "Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates" 16 : 1311-1319, 2005

16 Portier G, "Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial" 24 : 4976-4982, 2006

17 André T, "Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer" 350 : 2343-2351, 2004

18 Giacchetti S, "Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery" 10 : 663-669, 1999

19 Baize N, "Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases" 30 : 1349-1353, 2006

20 de Liguori Carino N, "Liver resection for colorectal liver metastases in older patients" 67 : 273-278, 2008

21 Aloia T, "Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases" 24 : 4983-4990, 2006

22 Bokemeyer C, "KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience" 26 (26): 2008

23 Van Cutsem E, "KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience" 26 (26): 2008

24 Karoui M, "Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases" 243 : 1-7, 2006

25 Gruenberger B, "Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases" 8 : 120-, 2008

26 Adam R, "Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy" 25 : 4593-4602, 2007

27 Adam R, "Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal" 8 : 347-353, 2001

28 Souglakos J, "FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal can cer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)" 94 : 798-805, 2006

29 Nordlinger B, "European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel" 20 : 985-992, 2009

30 Nordlinger B, "Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group" 43 : 2037-2045, 2007

31 Abdalla EK, "Colorectal metastases: resect or ablate?" 13 : 602-603, 2006

32 Vauthey JN, "Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases" 24 : 2065-2072, 2006

33 Cervantes A, "Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study" (Suppl 3) : S181-, 2005

34 Bokemeyer C, "Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS" (Suppl 5) : 4-, 2007

35 Folprecht G, "Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma" 17 : 450-456, 2006

36 Van Cutsem E, "CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)" (Suppl 5) : 4-, 2007

37 Gruenberger B, "Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer" 26 : 1830-1835, 2008

38 Korean Central Cancer Registry, "Annual Report of Cancer Registry in 2006, 2007, 2010"

39 André T, "Adjuvant treatment of colon cancer MOSAIC study's main results" 93 (93): S5-S9, 2006

40 Parks R, "Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents" 204 : 753-763, 2007

41 Mitry E, "Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials" 26 : 4906-4911, 2008

42 Mitry E, "Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials" 26 : 4906-4911, 2008

43 Ychou M, "A randomized phase III study comparing adjuvont 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer" 20 : 1964-1970, 2009